Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate

Journal of Nuclear Medicine

Volumn 52, Issue 8, 2011, Pages 1197-1203

  Ezziddin, Samer ^a   Sabet, Amir ^a   Heinemann, Florian ^a   Yong Hing, Charlotte J ^b   Ahmadzadehfar, Hojjat ^a   Guhlke, Stefan ^a   Höller, Tobias ^c   Willinek, Winfried ^a   Boy, Christian ^d   Biersack, Hans Jürgen ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Institute of Medical Biometry Informatics and Epidemiology   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

177Lu DOTA octreotate; Bone metastases; Neuroendocrine tumors; Oncology; Peptide receptor radionuclide therapy

Indexed keywords

CHROMOGRANIN A; DOTATOC GA 68; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; OCTREOTIDE LU 177; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PEPTIDE RECEPTOR RADIOISOTOPE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOISOTOPES; RECEPTORS, PEPTIDE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80051705007     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.090373     Document Type: Article

References (26)

1. Lebtahi R, Cadiot G, Delahaye N, et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med. 1999;40:1602-1608. (Pubitemid 29471148)
2. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083-1092. (Pubitemid 41815799)
3. Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006;47:223-233. (Pubitemid 46780886)
4. Durante C, Boukheris H, Dromain C, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer. 2009;16:585-597.
5. Meijer WG, van der Veer E, Jager PL, et al. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003;44:184-191.
6. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15:1083-1097.
7. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol. 1998;16:1040-1053. (Pubitemid 28108739)
8. 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214-1221.
9. Kos-Kudla B, O'Toole D, Falconi M, et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology. 2010;91:341-350.
10. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S. (Pubitemid 47619020)
11. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40:78-88.
12. 177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51:383-390.
13. 90Y-DOTATOC. J Nucl Med. 2005;46:1310-1316.
14. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401. (Pubitemid 44451313)
15. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757-762. (Pubitemid 47497934)
16. 177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging. 2003;30:312-315.
17. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917-920.
18. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253. (Pubitemid 23008970)
19. Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38:459-466.
20. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80-92.
21. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radio-labeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
22. 177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
23. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51:877-884. (Pubitemid 44030808)
24. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009;40:1262-1268.
25. 90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147-156.
26. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.